跳至主要内容
临床试验/CTIS2023-508229-28-00
CTIS2023-508229-28-00进行中(未招募)1 期

High-Intensity Inpatient MDMA-Assisted Psychotherapy for Treatment-Refractory Posttraumatic Stress Disorder: An Open-Label Pilot Study

Arq National Psychotrauma Centre0 个研究点目标入组 20 人开始时间: 2024年1月8日最近更新:
适应症

试验速览

阶段
1 期
状态
进行中(未招募)
发起方
入组人数
20

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 至 64(—)
性别
All

入选标准

  • Are at least 18 years, at the time of signing the informed consent., At Screening meet DSM-5 criteria for current PTSD with a symptom duration of at least 6 months., At Screening, have a PCL-5 score of 40 or greater (i.e., moderate to severe PTSD)., At screening, meet criteria for treatment-refractory PTSD, defined as having had at least two evidence-based trauma focused psychotherapies of at least 10 sessions per therapy.

排除标准

  • Have a current Personality Disorder, Have a diagnosis of uncontrolled hypertension, defined as repeated blood pressure readings of =140 mmHg systolic or =90 mmHg diastolic., Have a current eating disorder with compensatory behaviors, Have current major depressive disorder with psychotic features., Have a history of, or a current primary psychotic disorder or bipolar affective disorder type 1, Have a current moderate (not in early remission in the 3 months prior to enrollment and meets at least 5 of 11 diagnostic criteria per DSM-5) or severe alcohol or cannabis use disorder within the 12 months prior to enrollment (meets at least 6 of 11 diagnostic criteria per DSM-5)., Have an active illicit drug (other than cannabis) or prescription drug substance use disorder at any severity within 12 months prior to enrollment., Any participant presenting current serious suicide risk, as determined through psychiatric interview, responses to C-SSRS, and clinical judgment of the investigator will be excluded; however, history of suicide attempts is not an exclusion., Have a marked baseline QTcF interval >450 ms demonstrated on repeated ECG assessments., Have a history of any medical condition that could make receiving a sympathomimetic drug harmful because of increases in blood pressure and heart rate. This includes, but is not limited to, a history of myocardial infarction, cerebrovascular accident, heart failure, severe coronary artery disease, or aneurysm.

研究者

发起方
Arq National Psychotrauma Centre

相似试验